Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE"
Phase of Trial: Phase II
Latest Information Update: 27 Dec 2019
Price : $35 *
At a glance
- Drugs Denosumab (Primary)
- Indications Bone cancer; Giant cell tumours
- Focus Adverse reactions; Therapeutic Use
- Acronyms REDUCE
- 18 Nov 2019 Planned End Date changed from 1 Jan 2025 to 1 Mar 2025.
- 18 Nov 2019 Planned primary completion date changed from 1 Jan 2024 to 1 Sep 2024.
- 18 Nov 2019 Status changed from not yet recruiting to recruiting.